Papilloma virus humain 2019
Tema plagiatului este tot mai mult discutată în ultima vreme.
Apariția unor programe performante de căutare și identificare a similitudinilor între texte [ However, its associated risk of secondary infections remains a major issue, particularly when discussing long-term immunosuppressive treatment. Secondary viral infections can require delaying or discontinuing biological therapy, thus leading to a relapse or reactivation of the underlying disorder, and this can happen in patients with already limited therapeutic options.
Thorough screening papilloma virus humain 2019 timely diagnosis of viral reactivations are necessary in order to maximize the benefits and reduce the risks associated with biological therapy. Viruses frequently associated with such reactivations include hepatitis B and C viruses, cytomegalovirus, varicella-zoster virus, and Epstein-Barr virus. This review focuses on the risk of reactivation associated with biological therapy in papilloma virus humain 2019 with autoimmune diseases and underlying herpes virus, human papilloma virus and polyomavirus infections.
Keywords: biological therapy, viral infections, herpes virus, human papilloma virus, polyomavirus Full text PDF.